Dermata Therapeutics (DRMA)
NASDAQ:DRMA
Want to see DRMA full AI Analyst Report?
Total Valuation
Dermata Therapeutics has a market cap or net worth of $4.83M. The enterprise value is -$6.14M.
Market Cap$4.83M
Enterprise Value-$6.14M
Share Statistics
Dermata Therapeutics has 4,022,143 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding4,022,143
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Dermata Therapeutics’s return on equity (ROE) is -1.21 and return on invested capital (ROIC) is -124.91%.
Return on Equity (ROE)-1.21
Return on Assets (ROA)-0.96
Return on Invested Capital (ROIC)-124.91%
Return on Capital Employed (ROCE)-1.25
Revenue Per Employee0.00
Profits Per Employee-944.82M
Employee Count8
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Dermata Therapeutics is ―. Dermata Therapeutics’s PEG ratio is 0.00316.
PE Ratio―
PS Ratio0.00
PB Ratio0.35
Price to Fair Value0.35
Price to FCF>-0.01
Price to Operating Cash Flow-0.55
PEG Ratio0.00316
Income Statement
In the last 12 months, Dermata Therapeutics had revenue of 0.00 and earned -7.56M in profits. Earnings per share was -8.16.
Revenue0.00
Gross Profit0.00
Operating Income-7.77M
Pretax Income-7.56M
Net Income-7.56M
EBITDA-7.77M
Earnings Per Share (EPS)-8.16
Cash Flow
In the last 12 months, operating cash flow was -8.30M and capital expenditures -8.00, giving a free cash flow of -8.30M billion.
Operating Cash Flow-8.30M
Free Cash Flow-8.30M
Free Cash Flow per Share-2.06
Dividends & Yields
Dermata Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.02
52-Week Price Change-85.40%
50-Day Moving Average1.28
200-Day Moving Average2.94
Relative Strength Index (RSI)41.89
Average Volume (3m)249.42K
Important Dates
Dermata Therapeutics upcoming earnings date is Aug 18, 2026, After Close (Confirmed).
Last Earnings DateMay 13, 2026
Next Earnings DateAug 18, 2026
Ex-Dividend Date―
Financial Position
Dermata Therapeutics as a current ratio of 4.79, with Debt / Equity ratio of 0.00%
Current Ratio4.79
Quick Ratio4.79
Debt to Market Cap0.00
Net Debt to EBITDA0.97
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Dermata Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Dermata Therapeutics EV to EBITDA ratio is 0.69, with an EV/FCF ratio of <0.01.
EV to Sales0.00
EV to EBITDA0.69
EV to Free Cash Flow<0.01
EV to Operating Cash Flow<0.01
Balance Sheet
Dermata Therapeutics has $6.95M in cash and marketable securities with $0.00 in debt, giving a net cash position of $6.95M billion.
Cash & Marketable Securities$6.95M
Total Debt$0.00
Net Cash$6.95M
Net Cash Per Share$1.73
Tangible Book Value Per Share$6.72
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Dermata Therapeutics is $4.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$4.00
Price Target Upside86.92% Upside
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast―
EPS Growth Forecast93.30%